Articles From: Cubic Awarded Contract to Support F-35 Air Combat Training to Cubist Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Merck


SAN DIEGO, Jan.
Sign-up for Cubic Awarded Contract to Support F-35 Air Combat Training investment picks
SAN DIEGO, Calif., Oct.
Sign-up for Cubic Awarded Four Task Order Contracts to Support the U.S. Army Training and Education System investment picks
SAN DIEGO, Calif., Dec.
Sign-up for Cubic Awarded SPAWAR Contract to Supply Common Data Links investment picks
SAN DIEGO, Calif., Dec.
Sign-up for Cubic Completes Sydney Opal Card Rollout Early investment picks
Cubic Corporation (NYSE: CUB) will announce its fiscal year 2014 results by a press release distributed over a national wire service at approximately 4:00 p.m. Eastern Time on Tuesday, November 25, 2014.
Sign-up for Cubic Corporation to Release Fiscal Year 2014 Earnings and Host Conference Call November 25, 2014 investment picks
SAN DIEGO, Calif., Nov.
Sign-up for Cubic Integrates oti's WAVE NFC Device Into Its NextWave Mobile Mass Transit Platform investment picks
SAN DIEGO, Calif., Jan.
Sign-up for Cubic Joins Smart Cities Council, the Premier Coalition for Smart Sustainable Cities investment picks
SAN DIEGO, Calif., Oct.
Sign-up for Cubic Names Jan Marshall Vice President & Chief Information Officer investment picks
SAN DIEGO, Calif., Jan.
Sign-up for Cubic Names Tammy Breene Chief Learning Officer of Mission Support Services investment picks
SAN DIEGO, Calif., Dec.
Sign-up for Cubic Provides Iarnrod Eireann Irish Rail A Team Solution for "Putting the Customer First" investment picks
Cubic Corporation (NYSE: CUB) today reported its financial results for the fiscal year ended September 30, 2014.
Sign-up for Cubic Reports Fourth Quarter and Fiscal Year 2014 Results Including Record Quarterly Sales, Earnings, and Backlog investment picks
SAN DIEGO, Calif., Nov.
Sign-up for Cubic Selected to Deliver Interactive Training Courseware for the U.S. Army investment picks
Cubic Corporation (NYSE: CUB) today announced that Bradley H.
Sign-up for Cubic to Present at 14th Annual Raymond James Government Solutions & Technology Summit investment picks
Cubic Corporation (NYSE: CUB) today announced that Bradley H.
Sign-up for Cubic to Present at 17th Annual Needham Growth Conference investment picks
Cubic Corporation (NYSE: CUB) today announced that John D.
Sign-up for Cubic To Present At Credit Suisse Global Industrials Conference investment picks
2014/12/22
SAN DIEGO, Calif., Dec.
Sign-up for Cubic Transportation Systems President Steve Shewmaker Appointed to California Chamber of Commerce Board of Directors investment picks
SAN DIEGO, Calif., Dec.
Sign-up for Cubic Wins Coveted Best Tutorial Award at I/ITSEC 2014 investment picks
SAN DIEGO, Calif., Jan.
Sign-up for Cubic Wins Italian Army Follow-on Option Contract for Home Station Training investment picks
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food and Drug Administration (FDA) approved ZERBAXA™ (ceftolozane/tazobactam) for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by designated susceptible Gram-negative bacteria.
Sign-up for Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections investment picks
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights Agreement dated October 24, 2013 (CVR Agreement) from listing on the NASDAQ Global Select Market on February 2, 2015, contemporaneously with their redemption.
Sign-up for Cubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market investment picks
Cubist Pharmaceuticals, Inc .
Sign-up for Cubist Comments on CUBICIN Patent Litigation investment picks
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Patrick Vink, M.D., M.B.A., currently Senior Vice President and General Manager of Cubist’s International Business, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2015.
Sign-up for Cubist Names Dr. Patrick Vink Chief Operating Officer investment picks
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) breached their fiduciary duties in connection with the planned merger of the Company with Merck & Co., Inc. Cubist is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment.
Sign-up for CUBIST PHARMACEUTICALS ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck investment picks
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cubist Pharmaceuticals NEW YORK , Dec.
Sign-up for CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Cubic Awarded Contract to Support F-35 Air Combat Training to Cubist Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Merck
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent